Artal Group’s Iovance Biotherapeutics IOVA Stock Holding History

Artal Group’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,011,500	Closed	-$8.11M	–	47
2024 Q2	$8.11M	Buy	+1,011,500	New	+$10.8M	0.21%	46
2021 Q2	–	Sell	-400,000	Closed	-$12.7M	–	154
2021 Q1	$12.7M	Hold	400,000	–	–	0.22%	88
2020 Q4	$18.6M	Hold	400,000	–	–	0.4%	61
2020 Q3	$13.2M	Sell	400,000 -100,000	-20%	-$3.07M	0.32%	69
2020 Q2	$13.7M	Sell	500,000 -250,000	-33%	-$8.22M	0.38%	58
2020 Q1	$22.5M	Buy	750,000 +250,000	+50%	+$6.63M	0.95%	28
2019 Q4	$13.8M	Sell	500,000 -200,000	-29%	-$4.55M	0.53%	33
2019 Q3	$12.7M	Hold	700,000	–	–	0.51%	40
2019 Q2	$17.2M	Buy	700,000 +200,000	+40%	+$3.01M	0.69%	31
2019 Q1	$4.75M	Hold	500,000	–	–	0.19%	77
2018 Q4	$4.42M	Sell	500,000 -200,000	-29%	-$1.93M	0.16%	72
2018 Q3	$7.88M	Hold	700,000	–	–	0.2%	61
2018 Q2	$8.96M	Buy	700,000 +240,000	+52%	+$3.51M	0.19%	51
2018 Q1	$7.77M	Buy	+460,000	New	+$6.97M	0.1%	57

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Artal Group's IOVA Position: Q3 2024 in Review

Artal Group sold out of Iovance Biotherapeutics (IOVA) in Q3 2024, closing a stake of 1,011,500 shares — an estimated $8.11M sold.

Artal Group first reported a position in IOVA in Q1 2018 and held it in 14 quarters. The position peaked at $22.5M in Q1 2020. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

Artal Group reported no remaining Iovance Biotherapeutics position as of Q3 2024 after selling out during the quarter.
Artal Group sold 1,011,500 Iovance Biotherapeutics shares in Q3 2024, an estimated $8.11M.
Artal Group first reported a position in Iovance Biotherapeutics in Q1 2018 and held it in 14 quarters.
Artal Group's Iovance Biotherapeutics position peaked at $22.5M in Q1 2020.
286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.